Introduction {#S1}
============

Carbapenems are broad-spectrum beta-lactam agents that are frequently used as a last resort to treat serious infections caused by multidrug-resistant *Enterobacterales*. Resistance to carbapenems mainly depends on the production of carbapenemase enzymes. Carbapenemase-producing *Enterobacterales* (CPE) are increasingly reported and represent a major public health threat ([@B37]). The most clinically significant carbapenemases in *Enterobacterales* include the class A (KPC type), class B (metallo-β-lactamases \[MBLs\] \[i.e., VIM, IMP, and NDM types\]), and class D carbapenem-hydrolyzing β-lactamases (OXA-48-like enzymes) ([@B24]; [@B37]). NDM-1 and OXA-48 β-lactamases were initially identified in India and Turkey, respectively, and then spread to various countries worldwide including India, the Middle East, and Mediterranean countries ([@B43]; [@B14]; [@B31]; [@B12]; [@B36]). There is a lot of pilgrimage tourism and business travel between Iran and neighboring countries such as Iraq, Afghanistan, Pakistan, Turkey, and the Persian Gulf, so travelers with CPE colonization may be the vectors for spread of resistant strains. In the scope of outbreaks in Iran, diverse sequence types (STs) of dominant OXA-48- and NDM-producing *Klebsiella pneumoniae* have been identified in outbreaks or solitary case reports (STs 11, 893, 147, and 915) ([@B34], [@B35]). VIM-2-producing *K. pneumoniae* ST23 has been reported in Iran more recently ([@B19]).

The dissemination of OXA-48 and NDM-1 among *Enterobacterales* is mediated by the rapid spread of broad host-range conjugative plasmids. The *bla*~NDM--1~ gene has been detected on plasmids of various incompatibility groups: IncF, IncA/C, IncL/M, IncH, IncN, and IncX3 or untypeable ([@B40]). The *bla*~OXA--48~ gene has also been carried by various plasmids types including IncL/M, IncN, and IncA/C ([@B9]). Up until today, only one study has reported the finding of the prevalence and distribution of carbapenem resistance among *Enterobacterales* isolates in Iran ([@B32]). However, limited data about the sequence type of CRE isolates that has spread in Iran were available.

Here, we investigated the prevalence of ESBL and carbapenemase genes, to explore the distribution of plasmid replicons, and molecular epidemiology of CPE isolated in an Iranian hospital.

Materials and Methods {#S2}
=====================

Bacterial Strains {#S2.SS1}
-----------------

In this cross-sectional study, a total of 71 non-repetitive carbapenem-resistant *Enterobacterales* (CRE) clinical isolates resistant to at least one of the carbapenems (imipenem, meropenem, or ertapenem) were collected at the Loghman Hakim Educational Hospital, a 496-bed university hospital in Tehran (Iran) between February 2015 and March 2016. All isolates were identified by standard biochemical tests and API 20E (bioMérieux, Marcy-l'Etoile, France).

Antimicrobial Susceptibility Testing and Phenotypic Assay {#S2.SS2}
---------------------------------------------------------

Antimicrobial susceptibility testing of 10 antibiotics (imipenem, meropenem, ertapenem, cefepime, cefotaxime, ceftazidime, aztreonam, amikacin, gentamicin, and ciprofloxacin) was done by a standard disk diffusion method according to the [@B5] guidelines. The minimal inhibitory concentration (MIC) determinations for carbapenems (imipenem, meropenem, and ertapenem) were performed by gradient test strips (Liofilchem, Italy) based on [@B5] guidelines. MICs of colistin were determined by broth macrodilution method using colistin sulfate (Sigma-Aldrich), and EUCAST breakpoints were used for interpretation ([@B7]). *Escherichia coli* ATCC 25922 was used as quality control. Initial screening for the presence of carbapenemases was done by the modified Hodge test (MHT) test by following the [@B5] guideline.

Molecular Detection of Genes Encoding Carbapenemases and ESBLs {#S2.SS3}
--------------------------------------------------------------

Plasmid DNA was extracted using the Gene JET Plasmid Maxi-Prep Kit (Thermo Scientific). The presence of genes encoding carbapenemases (*bla*~KPC~, *bla*~GES~, *bla*~VIM~, *bla*~IMP~, *bla*~NDM~, and *bla*~OXA--48~) and extended-spectrum β-lactamases (ESBL) (*bla*~CTX--M~) and further beta-lactamases (*bla*~TEM~, *bla*~SHV~) were detected by PCR amplification using specific primers as described previously ([@B29]; [@B33]), followed by sequencing (Macrogen Research, Seoul, South Korea).

Molecular Typing {#S2.SS4}
----------------

The genetic relatedness of CPE isolates was investigated by pulsed-field gel electrophoresis (PFGE). The genomic DNA of the CPE isolates and reference marker *Salmonella* serotype Braenderup strain H9812 were digested by *Xba*I endonuclease, which was performed with a CHEF-DRIII system (Bio-Rad Laboratories) as previously described ([@B38]). A similarity coefficient was obtained using Dice coefficients. Cluster analysis was done with the unweighted pair group method with arithmetic averages (UPGMA). Isolates that exhibited similarity cut-off ≥80% of their banding patterns were considered to belong to the same clonal lineage (pulsotypes). Multilocus sequence typing (MLST) was performed according to the protocol described on the Pasteur Institute MLST website^[1](#footnote1){ref-type="fn"}^ for *K. pneumoniae*, MLST website for *E. coli*^[2](#footnote2){ref-type="fn"}^, and MLST website for *Enterobacter cloacae*^[3](#footnote3){ref-type="fn"}^.

Conjugation Experiments and PCR-Based Replicon Typing {#S2.SS5}
-----------------------------------------------------

Conjugation experiments were done using the *bla*~NDM--1~ and *bla*~OXA--48~ producers as the donors and *E. coli* K12 \[F^--^ lac ^+^ Nal (r)\] as the recipient strain (Filter mating). Isolates LO35, LO89, LO112, LO179, LO271, and LO273 which harbored only the *bla*~NDM--1~ or *bla*~OXA--48~ gene, and isolates LO149, LO155, and LO204, which harbored the *bla*~OXA--48~ and *bla*~NDM--1~ genes, were selected and used. Transconjugants were selected on a MacConkey agar plate containing 32 mg/L nalidixic acid (Sigma-Aldrich) and 1 mg/L MEM (MAST, Merseyside, United Kingdom) ([@B16]) and were confirmed to have *bla*~NDM--1~ and *bla*~OXA--48~ by PCR analysis. PCR-based replicon typing analysis (PBRT) was performed to determine the plasmid incompatibility (Inc) groups for all CPE strains and the obtained transconjugants ([@B4]).

Plasmid Extraction {#S2.SS6}
------------------

Plasmid DNA was prepared from an overnight culture with NucleoBond^®^ Xtra Midi kit for isolates according to the manufacturer's description for high-copy plasmid purification ([@B20]). Eluted plasmid DNA is then precipitated with isopropanol and washed with 70%; the dried pellet was reconstituted TE buffer, pH 8.0. The DNA concentration and purity were determined using the Qubit 3.0 Fluorometer.

Optical DNA Mapping in Nanochannels for Plasmid Analysis {#S2.SS7}
--------------------------------------------------------

The presence of the *bla*~NDM--1~ gene on plasmids from isolates LO94, LO204, LO271, LO247, LO64, LO63, LO89, and LO149 was investigated using optical DNA mapping ([@B22]). For this, Cas9 enzyme (PNA Bio Inc., Newbury Park, CA, United States) was used to make a site-specific cut at the *bla*~NDM--1~ gene (target gene sequence was 5′-CGGTATGGACGCGCTGCATG-3′, RNA was synthesized by Dharmacon Inc., Lafayette, CO, United States) on the plasmids ([@B21]). Cas9 will cut all the *bla*~NDM--1~ gene-carrying plasmids in each isolate at the same location which would show as a consensus cut site in the ODM data. For the plasmids not carrying the *bla*~NDM--1~ gene, we expected randomly distributed cuts.

After the Cas9 reaction, the plasmids were stained using YOYO-1 and Netropsin which created an emission intensity pattern along the DNA, with dark AT-rich regions and bright GC-rich regions ([@B25]; [@B23]). Netropsin prevents the binding of the fluorescent YOYO-1 to AT-rich regions which results in the formation of a variation in intensity, a DNA barcode. Plasmids were stretched to their full contour lengths by confining them in 100 × 150-nm^2^ nanofluidic channels and imaged using an EMCCD camera. For each of the eight isolates, hundreds of plasmids were imaged and analyzed. The barcodes were aligned, clustered based on similarity, and compared among the isolates using custom-built MATLAB routines ([@B20]). Lambda phage DNA was used as an internal control to correlate the length in pixels with the length in base pairs, and this correlation factor was then used to estimate plasmid sizes.

Results {#S3}
=======

Bacterial Isolates {#S3.SS1}
------------------

During the study period, 71 clinical CRE isolates were collected from 44 male and 27 female patients. These isolates mainly belonged to the species *K. pneumoniae* (56/71, 78.8%), *E. coli* (8/71, 11.2%), *Serratia marcescens* (5/71, 7%), and *E. cloacae* (2/71, 2.8%). Twenty-two isolates (31%) were isolated from an ICU poisoning ward, whereas the remaining of isolates were recovered from other ward. The majority of the isolates were from urine (30/71, 42.2%) and tracheal (24/71, 33.8%) specimens. Other sample types included blood (6/71; 8.4%), wound secretions (5/71; 7%), sputum (3/71; 4.2%), catheter (2/71; 2.8%), and cerebrospinal fluid (1/71; 1.4%).

Antimicrobial Susceptibility {#S3.SS2}
----------------------------

Susceptibility profiles against ten antimicrobials agents are listed in [Table 1](#T1){ref-type="table"}. As expected, the majority of the CRE isolates exhibited resistance to most β-lactams. Most of the isolates were also resistant to ciprofloxacin (70/71 98.6%) and gentamicin (42/71 59.1%). On the other hand, most of them were susceptible to amikacin (46/71 64.8%), and all isolates were susceptible to colistin, with MICs ≤ 1 mg/L. Based on phenotypic detection, 40 out of the 62 isolates (64.5%) were positive for MHT.

###### 

Clinical information and molecular characteristics of 71 carbapenem-resistant *Enterobacterales* isolated from a university hospital in Tehran, Iran.

  Patient/Strain   Species           Carbapenemase genes   Associated β-lactamases    Inc group^a^     ST       Specimen              Hospitalization unit   Resistance phenotype           MIC (μ g/ml)           
  ---------------- ----------------- --------------------- -------------------------- ---------------- -------- --------------------- ---------------------- ------------------------------ -------------- ------- -----
  **LO-1**         *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-106   IncFII, IncL/M   ST15     Tracheal              Emergency ICU          CAZ, CTX, FEP, CIP             8              8       8
  **LO-7**         *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-199   IncFII           ST893    Tracheal              Poisoning ICU          CAZ, CTX, FEP, GEN, CIP        8              8       8
  **LO-8**         *K. pneumoniae*   --                    CTX-M-15, TEM-1            ND               ND       Wound                 Poisoning ICU          CAZ, CTX, FEP, CIP             4              1       \>4
  **LO-17**        *K. pneumoniae*   NDM-1                 CTX-M-15, SHV-1            IncFII           ND       Urine                 Nerves of men          CAZ, CTX, FEP, AMK, GEN, CIP   8              32      64
  **LO-20**        *K. pneumoniae*   --                    CTX-M-15, TEM-1, SHV-1     ND               ND       Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             4              0/5     \>4
  **LO-21**        *K. pneumoniae*   --                    CTX-M-15, TEM-1, SHV-1     ND               ND       Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             2              1       \>4
  **LO-30**        *K. pneumoniae*   --                    CTX-M-15, TEM-1, SHV-1     ND               ND       Urine                 Poisoning ICU          CAZ, CTX, FEP, CIP             4              0/5     \>4
  **LO-36**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-1     IncFII           ND       Urine                 Poisoning ICU          CAZ, CTX, FEP, GEN, CIP        8              4       \>4
  **LO-56**        *K. pneumoniae*   --                    CTX-M-15, TEM-1            ND               ND       Wound                 Surgery                CAZ, CTX, FEP, CIP             2              1       \>4
  **LO-63**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    UT               ST147    Wound                 Surgery                CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-64**        *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             8              32      64
  **LO-68**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    IncFII           ST147    Sputum                Infectious             CAZ, CTX, FEP, AMK, GEN, CIP   8              32      256
  **LO-70**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-1     IncFII           ND       Tracheal              General ICU            CAZ, CTX, FEP, CIP             8              8       8
  **LO-77**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    IncFII           ST147    Tracheal              General ICU            CAZ, CTX, FEP, AMK, GEN, CIP   8              8       32
  **LO-78**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-12    UT               ST147    Tracheal              Emergency ICU          CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-80**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    IncFII           ST147    Urine                 Infectious             CAZ, CTX, FEP, AMK, GEN, CIP   8              32      64
  **LO-82**        *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Urine                 Internal emergency     CAZ, CTX, FEP, AM, GEN, CIP    8              32      256
  **LO-88**        *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-1     IncL/M           ND       Urine                 Internal emergency     CAZ, CTX, FEP, GEN, CIP        8              4       4
  **LO-89**        *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    IncFII           ST147    Urine                 Outpatient             CAZ, CTX, FEP, AMK, GEN, CIP   8              16      32
  **LO-91**        *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-1     IncL/M           ST377    Tracheal              Emergency ICU          CAZ, CTX, FEP, AM, GEN, CIP    8              8       8
  **LO-94**        *K. pneumoniae*   NDM-1                 CTX-M-15, SHV-199          UT               ST16     Tracheal              Infectious             CAZ, CTX, FEP, GEN, CIP        8              4       4
  **LO-95**        *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Tracheal              Internal emergency     CAZ, CTX, FEP, GEN, CIP        8              2       \>4
  **LO-97**        *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV       IncL/M           ST16     Urine                 Emergency ICU          CAZ, CTX, FEP, AMK, GEN, CIP   8              2       \>4
  **LO-106**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-1     IncFII           ND       Blood                 Poisoning ICU          CAZ, CTX, FEP, AMK, GEN, CIP   4              4       2
  **LO-110**       *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             4              2       \>4
  **LO-114**       *K. pneumoniae*   NDM-1                 CTX-M-15, SHV-1            IncFII           ST657    Tracheal              Internal emergency     CAZ, CTX, FEP, CIP             8              8       8
  **LO-119**       *K. pneumoniae*   --                    CTX-M-15, TEM-1, SHV-1     ND               ND       Urine                 Emergency ICU          CAZ, CTX, FEP, GEN, CIP        2              1       \>4
  **LO-121**       *K. pneumoniae*   OXA-48                TEM-1, SHV-199             IncL/M           ST893    Sputum                Internal emergency     CAZ, CTX, FEP, CIP             8              8       8
  **LO-123**       *K. pneumoniae*   NDM-1                 CTX-M-15, SHV-1            IncFII           ST35     Tracheal              Poisoning ICU          CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-125**       *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-182   IncL/M           ST11     Urine                 Internal emergency     CAZ, CTX, FEP, CIP             4              2       \>4
  **LO-126**       *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Urine                 Poisoning ICU          CAZ, CTX, FEP, CIP             4              1       \>4
  **LO-147**       *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-106   IncFII, IncL/M   ST15     Tracheal              General ICU            CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-149**       *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-106   IncFII, IncL/M   ST15     Tracheal              Poisoning ICU          CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-154**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-199   UT               ST16     Urine                 Internal emergency     CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-155**       *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             8              32      32
  **LO-179**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-199   IncFII           ST16     Urine                 Infectious             CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **LO-181**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-1     IncFII           ST147    Urine                 Surgery                CAZ, CTX, FEP, AMK, GEN, CIP   8              16      8
  **LO-191**       *K. pneumoniae*   NDM-1                 --                         IncFII           ST1308   Wound                 Surgery                CAZ, CTX, FEP                  8              4       4
  **LO-204**       *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-106   IncFII, IncL/M   ST15     Catheter              Surgery                CAZ, CTX, FEP, AMK, GEN, CIP   8              32      256
  **LO-216**       *K. pneumoniae*   --                    CTX-M-15, SHV-199          ND               ND       Urine                 Internal emergency     CAZ, CTX, FEP, CIP             2              0/5     \>4
  **LO-217**       *K. pneumoniae*   NDM-1                 CTX-M-15, SHV-199          IncFII           ST16     Urine                 General ICU            CAZ, CTX, FEP, GEN, CIP        8              16      24
  **LO-246**       *K. pneumoniae*   --                    CTX-M-15, TEM-1, SHV-1     ND               ND       Tracheal              Poisoning ICU          CAZ, CTX, FEP, AMK, GEN, CIP   4              2       \>4
  **LO-247**       *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-199   IncFII           ND       Catheter              Neurosurgery           CAZ, CTX, FEP, CIP             8              8       4
  **LO-251**       *K. pneumoniae*   NDM-1, OXA-48         CTX-M-15, TEM-1, SHV-199   IncL/M           ST893    Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             8              4       2
  **LO-261**       *K. pneumoniae*   OXA-48                TEM-1, SHV-199             IncL/M           ST893    Tracheal              Infectious             CAZ, CTX, FEP, CIP             8              4       4
  **LO-262**       *K. pneumoniae*   NDM-1                 TEM-1, SHV-172             IncFII           ST147    Urine                 Neurosurgery           CAZ, CTX, FEP, AMK, GEN, CIP   8              32      256
  **LO-263**       *K. pneumoniae*   NDM-1, OXA-48         TEM-1, SHV-12              IncL/M           ST147    Urine                 Neurosurgery           CAZ, CTX, FEP, AMK, GEN, CIP   8              32      128
  **LO-264**       *K. pneumoniae*   --                    CTX-M-15, TEM-1, SHV-1     ND               ND       Tracheal              Poisoning ICU          CAZ, CTX, FEP, GEN, CIP        4              ND      ND
  **LO-268**       *K. pneumoniae*   OXA-48                TEM-1                      IncL/M           ST23     Sputum                Neurosurgery           CAZ, CTX, FEP, GEN, CIP        8              4       4
  **LO-269**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    IncFII           ST147    Urine                 Internal emergency     CAZ, CTX, FEP, AMK, GEN, CIP   8              16      4
  **LO-270**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-11    IncFII           ST147    Urine                 Infectious             CAZ, CTX, FEP, AMK, GEN, CIP   8              16      4
  **LO-271**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-12    IncFII           ST147    Blood                 Infectious             CAZ, CTX, FEP, AMK, GEN, CIP   8              16      32
  **LO-272**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1, SHV-1     IncFII           ST377    Urine                 Infectious             CAZ, CTX, FEP, AMK, GEN, CIP   8              32      128
  **LO-277**       *K. pneumoniae*   NDM-1                 CTX-M-15, TEM-1            UT               ST2012   Cerebrospinal fluid   Infectious             CAZ, CTX, FEP, CIP             8              8       8
  **LO-278**       *K. pneumoniae*   OXA-48                CTX-M-15, TEM-1, SHV-1     IncL/M           ST377    Blood                 Infectious             CAZ, CTX, FEP, GEN, CIP        8              16      8
  **LO-279**       *K. pneumoniae*   NDM-1                 CTX-M-15, SHV-11           IncFII           ST147    Blood                 Infectious             CAZ, CTX, FEP, GEN, CIP        8              32      32
  **LO-4**         *E. coli*         OXA-48                CTX-M-15                   IncL/M           ND       Urine                 Internal of women      CAZ, CTX, FEP, CIP             1              0/125   \>4
  **LO-35**        *E. coli*         OXA-48                CTX-M-15                   IncL/M           ST410    Urine                 Poisoning ICU          CAZ, CTX, FEP, GEN, CIP        0/5            0/125   \>4
  **LO-96**        *E. coli*         OXA-48                CTX-M-15, TEM-1            IncL/M           ND       Wound                 Infectious             CAZ, CTX, FEP, GEN, CIP        1              0/5     \>4
  **LO-175**       *E. coli*         OXA-48                CTX-M-15, TEM-1            IncL/M           ST1431   Urine                 Emergency ICU          CAZ, CTX, FEP, CIP             2              0/5     \>4
  **LO-180**       *E. coli*         OXA-48                CTX-M-15, TEM-1            IncL/M           ST3134   Urine                 Outpatient             CAZ, CTX, FEP, AMK, GEN, CIP   1              0/125   \>4
  **LO-183**       *E. coli*         OXA-48                --                         IncL/M           ST5114   Urine                 Outpatient             CAZ, CTX, FEP, CIP             2              0/125   \>4
  **LO-231**       *E. coli*         NDM-1                 CTX-M-15, TEM-1            IncA/C           ST131    Urine                 Internal emergency     CAZ, CTX, FEP, GEN, CIP        2              1       \>4
  **LO-233**       *E. coli*         OXA-48                CTX-M-15                   IncL/M           ST5114   Urine                 Emergency ICU          CAZ, CTX, FEP, CIP             1              0/125   \>4
  **LO-112**       *S. marcescens*   OXA-48                CTX-M-15, TEM-1, SHV-12    IncL/M           --       Blood                 Poisoning ICU          CAZ, CTX, FEP, CIP             8              16      4
  **LO-113**       *S. marcescens*   OXA-48                CTX-M-15, TEM-1, SHV-12    IncL/M           --       Blood                 Poisoning ICU          CAZ, CTX, FEP, CIP             8              32      32
  **LO-133**       *S. marcescens*   OXA-48                CTX-M-15, TEM-1, SHV-12    IncL/M           --       Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             8              16      8
  **LO-166**       *S. marcescens*   OXA-48                CTX-M-15, TEM-1, SHV-12    IncL/M           --       Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             8              16      16
  **LO-207**       *S. marcescens*   OXA-48                CTX-M-15, TEM-1, SHV-12    IncL/M           --       Tracheal              Poisoning ICU          CAZ, CTX, FEP, CIP             8              16      16
  **LO-273**       *E. cloacae*      NDM-1                 CTX-M-15, TEM-1            IncFII           ST78     Urine                 Outpatient             CAZ, CTX, FEP, AMK, GEN, CIP   8              32      32
  **N-20-LO**      *E. cloacae*      NDM-1                 CTX-M-15, TEM-1            IncFII           ST175    Urine                 General ICU            CAZ, CTX, FEP, GEN, CIP        8              4       4

a

Incompatibility (Inc) group. ND, not determined; UT, untypeable.; F, female; M, male; MIC, minimal inhibitory concentrations; S, susceptible; IPM, imipenem; MEM, meropenem; ETP, ertapenem; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; ATM, aztreonam; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; CST, colistin. Only carbapenemase producing isolates were MLST analyzed.

Carbapenemase and ESBL Genes {#S3.SS3}
----------------------------

The genotyping results of carbapenemase and ESBL genes among CRE isolates are shown in [Table 1](#T1){ref-type="table"}. Of the 71 CRE isolates, 62 were carbapenemase producers. Among the 62 carbapenemase-producing isolates, 29 were found positive for the *bla*~NDM--1~ gene, 23 were positive for the *bla*~OXA--48~ gene, and ten of the *bla*~NDM--1~-positive isolates co-harbored *bla*~OXA--48~ genes. Among the *bla*~NDM--1~-positive *Enterobacterales* species, 26 *K. pneumoniae* isolates, two *E. cloacae* isolates, and a single *E. coli* isolate were identified. The twenty-three *bla*~OXA--48~ producers were *K. pneumoniae* (*n* = 11), *E. coli* (*n* = 7), and *S. marcescens* (*n* = 5). All the ten isolates co-producing *bla*~NDM--1~ and *bla*~OXA--48~ were *K. pneumoniae*. Other carbapenemase genes (*bla*~GES~, *bla*~KPC~ *bla*~VIM~, and *bla*~IMP~) were not detected. Among the 71 CRE isolates, 91.5% (65/71) ESBL producers were observed. Out of 65 ESBL producers, 64 (98.4%) harbored *bla*~CTX--M--15~ and eight (12.3%) harbored *bla*~SHV--12~; furthermore, a lot of isolates harbored additional *bla*~TEM/SHV~ genes.

Clonal Relationship of CRE Isolates {#S3.SS4}
-----------------------------------

Based on a cutoff of 80% genetic similarity, PFGE revealed that 44 carbapenemase-positive *K. pneumoniae* isolates could be categorized in seven clusters A (4 isolates), B (10 isolates), C (3 isolates), D (4 isolates), E (5 isolates), F (2 isolates), and G (5 isolates), while 11 isolates appeared to be singletons ([Figure 1](#F1){ref-type="fig"}). Clusters E, F, and G belonged to ST147, while clusters A, B, C, and D were categorized as ST16, ST893, ST377, and ST15, respectively. The eight NDM-1- and OXA-48-producing *E. coli* isolates were clonally unrelated by PFGE ([Figure 2](#F2){ref-type="fig"}), including two belonging to the same sequence type (ST5114). The PFGE patterns of five OXA-48-positive *S. marcescens* isolates showed 100% similarity, but the two NDM-1-positive *E. cloacae* had distinct PFGE patterns ([Figure 3](#F3){ref-type="fig"}).

![Dendrogram based on PFGE of 44 isolates of CPKP and their ST determined via MLST. ND, not determined.](fmicb-11-00936-g001){#F1}

![Dendrogram based on PFGE of 8 isolates of carbapenemase-producing *Escherichia coli* and their ST determined via MLST. ND, not determined.](fmicb-11-00936-g002){#F2}

![*Serratia marcescens* and *E nterobacter cloacae* are grouped together in the same dendrogram for comparison. Dendrogram based on PFGE of 5 isolates of OXA-48-producing *S. marcescens* and 2 NDM-1-producing *E. cloacae.*](fmicb-11-00936-g003){#F3}

Plasmid Replicon Typing and Conjugation Assay {#S3.SS5}
---------------------------------------------

The *bla*~NDM--1~ gene was identified on an IncFII-type plasmid for twenty-six *K. pneumoniae* and two *E. cloacae* isolates and on an IncA/C-type plasmid for a single *E. coli* isolate, while the *bla*~OXA--48~ gene was identified on an IncL/M-type plasmid for nineteen *K. pneumoniae*, seven *E. coli*, and five *S. marcescens* isolates. In the six *K. pneumoniae* isolates, we could not identify the incompatibility group.

Conjugation experiments revealed that all of the NDM-1 and OXA-48 plasmids were successfully transferred to *E. coli* K12, conferring resistance to carbapenems and cephalosporins in transconjugants. In addition, co-transfer of *bla*~NDM--1~, *bla*~OXA--48~, and other resistance determinants (*bla*~CTX--M~, *bla*~TEM~, and *bla*~SHV~) was observed in several isolates ([Table 2](#T2){ref-type="table"}). Plasmid gel extraction followed by PCR amplification of the transconjugants revealed that the *bla*~OXA--48~ gene was harbored on transferable plasmids belonging to the IncL/M incompatibility group, while the *bla*~NDM--1~ gene was located on conjugative plasmids. Transconjugant Tc-Lo204 had two different plasmids, and the size of one plasmid was ∼140 kb with *bla*~NDM--1~ and the other one was ∼135 kb with *bla*~OXA--48~. Notably, all *bla*~OXA--48~-positive conjugative plasmids co-harbored beta-lactamase gene *bla*~CTX--M--15~.

###### 

Microbiological characteristics of nine clinical CPE isolates and their transconjugants.

  Isolate        Species           ST      MIC (mg/L)   Antimicrobial resistance phenotype   β-lactamase(s)   Size of plasmids               Inc group                                                     
  -------------- ----------------- ------- ------------ ------------------------------------ ---------------- ------------------------------ ----------------------------------- ------------------------- ----------------
  LO-35          *E. coli*         410     0.5          0/125                                \>4              CAZ, CTX, FEP, CIP             OXA-48, CTX-M-15                    ∼39 kb                    IncL/M
  Tc-LO-35^a^                      --      0/125        0/125                                \>4              CAZ, CTX, FEP                  OXA-48, CTX-M-15                    ∼39 kb                    IncL/M
  LO-89          *K. pneumoniae*   ST147   8            16                                   32               CAZ, CTX, FEP, AMK, GEN, CIP   NDM-1, CTX-M-15, TEM, SHV           104.8 ± 3.6               IncFII
  Tc-LO-89^a^                      --      4            8                                    ND               CAZ, CTX, FEP                  NDM-1, CTX-M-15, TEM                --                        IncFII
  LO-112         *S. marcescens*   --      8            16                                   4                CAZ, CTX, FEP, CIP             OXA-48, CTX-M-15, TEM, SHV          ∼39 kb                    IncL/M
  Tc-LO-112^a^                     --      4            4                                    2                CAZ, CTX, FEP                  OXA-48, CTX-M-15, TEM               ∼39 kb                    IncL/M
  LO-149         *K. pneumoniae*   ST15    8            32                                   32               CAZ, CTX, FEP, AMK, GEN, CIP   NDM-1, OXA-48, CTX-M-15, TEM, SHV   130.6 ± 3.2               IncFII, IncL/M
  Tc-LO-149^a^                     --      8            16                                   8                CAZ, CTX, FEP, AMK, GEN        NDM-1, SHV                          130.6 ± 3.2               IncFII
  LO-155         *K. pneumoniae*   ST893   8            32                                   32               CAZ, CTX, FEP, CIP             NDM-1, OXA-48, CTX-M-15, TEM, SHV   --                        IncL/M
  Tc-LO-155^a^                     --      8            8                                    \>4              CAZ, CTX, FEP                  OXA-48, CTX-M-15, TEM               --                        IncL/M
  LO-179         *K. pneumoniae*   ST16    8            32                                   24               CAZ, CTX, FEP, AMK, GEN, CIP   NDM-1, CTX-M-15, TEM, SHV           --                        IncFII
  Tc-LO-179^a^                     --      4            4                                    ND               CAZ, CTX, FEP, AMK, GEN        NDM-1, TEM                          --                        IncFII
  LO-204         *K. pneumoniae*   ST15    8            32                                   256              CAZ, CTX, FEP, AMK, GEN, CIP   NDM-1, OXA-48, CTX-M-15, TEM, SHV   140.2 ± 3.2 135.1 ± 3.0   IncFII, IncL/M
  Tc-LO-204^a^                     --      8            ND                                   ND               CAZ, CTX, FEP, AMK, GEN        NDM-1, OXA-48, TEM, SHV             140.2 ± 3.2 135.1 ± 3.0   IncFII, IncL/M
  LO-271         *K. pneumoniae*   ST147   8            16                                   32               CAZ, CTX, FEP, AMK, GEN, CIP   NDM-1, CTX-M-15, TEM, SHV           107.4 ± 4.6 86.3 ± 4.8    IncFII
  Tc-LO-271^a^                     --      4            8                                    ND               CAZ, CTX, FEP                  NDM-1, CTX-M-15, TEM                --                        IncFII
  LO-273         *E. cloacae*      ST78    8            32                                   24               CAZ, CTX, FEP, AMK, GEN, CIP   NDM-1, CTX-M-15                     --                        IncFII
  Tc-LO-273^a^                     --      8            ND                                   ND               CAZ, CTX, FEP, AMK, GEN        NDM-1                               ∼50 kb                    IncFII

MIC, minimal inhibitory concentrations; ERT, ertapenem, MEM, meropenem; IPM, imipenem; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AMK, amikacin; GEN, gentamicin, CIP, ciprofloxacin, CST, colistin.

a

Tc,

E. coli

K12 transconjugants selected in media containing 1 μg/ml MEM. Plasmid size for LO-89, LO-149, LO-204, and LO-271 isolates was estimated by ODM; that for other isolates was estimated by plasmid preparation.

Optical DNA Mapping {#S3.SS6}
-------------------

The presence of the *bla*~NDM--1~ gene on plasmids of isolates LO94, LO204, LO271, LO247, LO64, LO63, LO89, and LO149 was characterized using optical DNA mapping (ODM). [Table 3](#T3){ref-type="table"} presents a summary of the ODM data for the *bla*~NDM--1~-carrying plasmids in these eight *K. pneumoniae* strains. DNA barcodes for each isolate were clustered based on similarity, and clusters with consensus cut sites (with at least nine barcodes) were used to infer the Cas9 cutting, suggesting the presence of the *bla*~NDM--1~ gene on the plasmids ([@B22]). For isolate LO271, two plasmids (∼86 kb and ∼107 kb) carrying the *bla*~NDM--1~ gene were identified. For isolate LO204, two plasmids of length ∼140 kb and ∼135 kb were found; however, only the ∼140-kb plasmid carried the *bla*~NDM--1~ gene. The remaining six isolates carried only one plasmid in the size range ∼110 kb to ∼130 kb carrying the *bla*~NDM--1~ gene.

###### 

Clinical and ODM information about *bla*~NDM--1~-carrying plasmids in eight *K. pneumoniae* strains isolated from Loghman hospital in Tehran.

  Strain no.   MIC (μ g/ml)   Species   ST    *bla*~NDM--1~ carrying plasmids (kbp)                        
  ------------ -------------- --------- ----- --------------------------------------- ------ ------------- ---------------
  LO-94        8              4         4     *K. pneumoniae*                         16     126.3 + 5.1   
  LO-204       8              32        256   *K. pneumoniae*                         15     140.2 ± 3.2   135.1 ± 3.0\*
  LO-271       8              16        32    *K. pneumoniae*                         147    86.3 ± 4.8    107.4 ± 4.6
  LO-247\*     8              8         4     *K. pneumoniae*                         ND\*   110.7 ± 2.5   
  LO-64        8              32        48    *K. pneumoniae*                         893    125.4 ± 3.0   
  LO-63        8              32        32    *K. pneumoniae*                         147    122.7 ± 2.9   
  LO-89        8              16        32    *K. pneumoniae*                         147    104.8 ± 3.6   
  LO-149       8              32        32    *K. pneumoniae*                         15     130.6 ± 3.2   

\*Did not carry

bla

NDM--1

. ND, not determined.

After plasmid size estimation and *bla*~NDM--1~ gene detection, we compared the consensus barcodes among the eight isolates ([Figure 4](#F4){ref-type="fig"}). The ODM assay showed that identical plasmids with the same size (∼125 kb) and the same location of the *bla*~NDM--1~ were found in LO63 and LO64 ([Figure 4A](#F4){ref-type="fig"}). These isolates belong to sequence types ST147 and ST893, respectively ([Figure 1](#F1){ref-type="fig"}), suggesting a possible transmission of plasmid from one strain to the other. Similarly structured plasmids were found in LO89 and LO271 (∼107 kb) ([Figure 4A](#F4){ref-type="fig"}); they both belong to the same sequence type, ST147. By visual inspection, it appears that large regions of the plasmids of isolates LO63, LO64, LO89, and LO271 ([Figure 4A](#F4){ref-type="fig"}) are similar, further accentuated by the fact that the *bla*~NDM--1~ gene is located at the same position. There are however, other regions that are not the same, and the size differs (plasmids from LO63, LO64, and LO89 were ∼125 kb while the plasmid from LO271 was ∼107 kb). The plasmids from the other isolates do not match among each other ([Figure 4B](#F4){ref-type="fig"}) or with the plasmids in [Figure 4A](#F4){ref-type="fig"}. In total, we therefore found seven different plasmids carrying the *bla*~NDM--1~ gene.

![Plasmid barcodes of *bla*~NDM--1~-carrying plasmids in eight *Klebsiella pneumoniae* strains. Since the plasmids are linearized by Cas9-targeting *bla*~NDM--1~, all barcode ends are where we locate the *bla*~NDM--1~ gene. For the samples containing two *bla*~NDM--1~ plasmids, sizes are written in brackets to differentiate the plasmids. **(A)** Identical plasmids with the same sizes (∼125 kb) and the same location of *bla*~NDM--1~. **(B)** Plasmids encoding *bla*~NDM--1~ that do not match among each other. LO-271 (107.4) and LO-64 were plotted here for reference.](fmicb-11-00936-g004){#F4}

Discussion {#S4}
==========

Herein, we found 71 CRE in a period of 1 year with a lot of CPE species from patients in the same hospital in Tehran, Iran, and major dissemination of the *bla*~NDM--1~ and *bla*~OXA--48~ genes, which might be considered endemic in the geographical area, through the spread of conjugative plasmids.

The co-occurrence of NDM-1- and OXA-48-producing *Enterobacterales* species is also considerable since the identification of NDM-1 and OXA-48 producers in Iran ([@B36]), Lebanon ([@B6]), and Kuwait ([@B11]) shows that these carbapenemases, known to be widespread in the Indian subcontinent, may also be widespread in the Middle East. In our study, the majority of the NDM-1- and OXA-48-producing *Enterobacterales* isolates co-harbored at least one ESBL gene which is concordant with previous reports ([@B39]; [@B34]). In this study, nine carbapenem-resistant *K. pneumoniae* were identified; this may be due to other resistance mechanisms (e.g., more rare carbapenemases, porin loss, AmpC enzymes) that were not investigated in detail in this study.

The plasmid incompatibility types IncFII and IncA/C were identified among the NDM-1-producing isolates, while only IncL/M was detected among OXA-48 producers ([Table 1](#T1){ref-type="table"}). These replicon types have been reported in *Enterobacterales* species in many regions of the world ([@B3]; [@B9]; [@B15]; [@B36]). Also, [@B42] demonstrated that the potential transmission of mobilized Tn125-like transposons with *bla*~NDM--1~ into different plasmids among *Enterobacterales* species ([@B42]). Conjugation assays were successful for all CPE isolates and allowed the identification of *bla*~OXA--48~-carrying plasmids belonging to the IncL/M incompatibility group in all transconjugants, with the exception of Tc-LO-149 ([Table 2](#T2){ref-type="table"}). Also, analysis of transconjugants showed that the *bla*~NDM--1~ carried on transferable plasmids belonging to the IncFII and IncA/C incompatibility group, respectively.

The identification of conjugative plasmids harboring *bla*~NDM--1~ and *bla*~OXA--48~ genes in CRE isolates shows that these plasmids contribute to the dissemination of carbapenemase genes among *Enterobacterales* species. Therefore, resistance to carbapenems in CRE isolates is likely to be associated with the spread of these genes in this hospital, which is consistent with previous studies ([@B12]; [@B15]; [@B34]).

Pulsed-field gel electrophoresis revealed that different clones of carbapenemase-producing *K. pneumoniae* (CPKP) were present, and there were two predominated clones that were identified as ST147 and ST893, comprising 13 and 10 isolates, respectively. ST147 and ST893 have been circulating in this hospital setting during the period of investigation, indicating two separate outbreaks, with the ICU poisoning acting as the epicenter. Indeed, hospital outbreaks of ST147 NDM-1-producing *K. pneumoniae* are common in Europe ([@B2]; [@B8]), whereas the outbreak of OXA-48-producing ST893 *K. pneumoniae* was only reported from Isfahan, Iran ([@B35]).

The dominant endemic sequence type *K. pneumoniae* in our study was ST147 which co*-*harbored NDM-1 and *bla*~CTX--M--15~, *bla*~TEM--1~, and *bla*~SHV--11,12,172~ genes. As an internationally successful sequence type, ST147 has previously been linked to the spread of ESBLs (especially CTX-M-15), OXA-48, VIM, and KPC and recently also to NDM-1 in various countries ([@B2]; [@B18]). In addition, ST893, the second most common sequence type in this study that co-harbored *bla*~CTX--M--15~, *bla*~TEM--1~, and *bla*~SHV--199~, has also only been reported in Iran among CPKP isolates which has been associated with ESBL and carbapenemase genes ([@B35]). Several other STs were found among CPKP isolates, including ST16 (cluster A), ST377 (cluster C), ST15 (cluster D), ST11, ST23, ST35, ST2012, ST657, and ST1308.

The four isolates of ST15 (cluster D) were isolated from patients in four ward. All isolates carried *bla*~NDM--1~ in combination of *bla*~OXA--48~ and *bla*~CTX--M--15~, *bla*~TEM--1~, and *bla*~SHV--106~ genes. *K. pneumoniae* ST15 represents a single locus variant of ST14 and is currently widely disseminated among CTX-M-15- and OXA-48- or NDM-1-producing *K. pneumoniae* isolates in different geographical regions ([@B30]; [@B15]; [@B1]; [@B13]).

The four NDM-1- and one OXA-48-producing *K. pneumoniae* in our study belonged to ST16 and were positive for *bla*~CTX--M--15~ and *bla*~SHV--199~ genes. It is noteworthy that OXA-48-producing ST16 have also been described in *K. pneumoniae* that caused outbreaks in two hospitals in different regions of Spain ([@B26]). Furthermore, two OXA-48- and one NDM-1-producing *K. pneumoniae* were isolated from three patients in two different ward. They belonged to ST377, which has previously not been reported as a carbapenemase producer. Finally, one OXA-48-producing *K. pneumoniae* isolate that co-carried *bla*~CTX--M--15~, *bla*~TEM--1~, and *bla*~SHV--182~ was identified as ST11. The *bla*~OXA--48~-harboring IncL/M plasmids have been mainly described in *K. pneumoniae* ST11 in different countries including, Spain ([@B3]), Taiwan ([@B17]), and Greece ([@B41]).

Considering this study and our previous study in Isfahan province ([@B35]), the main *K. pneumoniae* STs that were identified in Iran were ST893, ST11, and ST147. This scenario suggests that these STs have likely been circulating in Iran in recent years. Our results show that, in general, the population structure of CP *E. coli* is more diverse than that of CPKP, which is essentially similar to the findings of other studies ([@B31]; [@B15]; [@B36]). We detected *E. coli* ST410, ST1431, ST3134, and ST5114 which have been reported as harboring *bla*~OXA--48~ and ESBL genes. Moreover, we identified only one ST131 of *E. coli* which harbored *bla*~NDM--1~, *bla*~CTX--M--15~, and *bla*~TEM--1~ genes. The association of NDM-1 and ESBL genes with the pandemic clone ST131 has been previously reported from several countries ([@B28], [@B27]).

The two NDM-1-positive *E. cloacae* isolates were genetically not related and belonged to two STs, ST78 and ST175, both also carried *bla*~CTX--M--15~ and *bla*~TEM--1~ genes, while the five *S. marcescens* isolates were considered identical (\>99% similarity). Interestingly, looking at the hospitalization ward from which the patients originated, several infections were detected at the ICU poisoning, with a total of five patients harboring this OXA-48-producing *S. marcescens* strain which co-carried further beta-lactamase genes (*bla*~CTX--M--15~, *bla*~SHV--12~, and *bla*~TEM--1~). Our results showed that this OXA-48-producing *S. marcescens* strain was isolated among inpatients who shared a room. Therefore, it is possible that the spread of this strain from patient to patient occurred. To the best of our knowledge, this is the first report of an outbreak of OXA-48-producing *S. marcescens* that co-harbored ESBL genes in Iran. A small hospital outbreak linked to OXA-48-producing *S. marcescens* has been previously reported in Lebanon ([@B10]). The exact mechanism of CPE spread in Iran is not well understood. Our previous study in July to November 2015 in two university hospitals in Iran showed that the rate of fecal carriage of CRE among inpatients is high (37.9%) and predominant species were *K. pneumoniae*, *E. coli*, *E. cloacae*, and *Proteus mirabilis*, which harbored the *bla*~NDM--1~ and *bla*~OXA--48~ genes ([@B34]). The circulation of *bla*~NDM--1~ and *bla*~OXA--48~ carbapenemase genes in the general population may result in a further spread by traveling and continuous introduction into the hospitals.

In conclusion, findings of extensive analysis of plasmids in the present study showed the enormous potential of spread of carbapenemase genes by horizontal gene transfer via plasmids and we identified the conjugative plasmids carrying the *bla*~NDM--1~ and *bla*~OXA--48~ genes in different *Enterobacterales* species that co-produce ESBLs. Here, in one Tehran hospital, we report two separate outbreaks of NDM-1-producing ST147 and OXA-48-producing ST893 *K. pneumoniae* STs. Furthermore, an outbreak with OXA-48-producing *S. marcescens* was observed. It is necessary to continue epidemiological and active surveillance to improve the control and prevention of infections associated with CPE isolates in healthcare facilities.
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